Angiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trial.

Angiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trial.

Treatments that reduce inflammation and cardiovascular disease (CVD) risk among individuals with HIV infection receiving effective antiretroviral therapy (ART) are needed.We conducted a 2 × 2 factorial feasibility study of lisinopril (L) (10 mg daily) vs L-placebo in combination with pravastatin (P)...

Full description

Bibliographic Details
Main Authors: Jason V Baker, Kathleen Huppler Hullsiek, Rachel Prosser, Daniel Duprez, Richard Grimm, Russell P Tracy, Frank Rhame, Keith Henry, James D Neaton
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3474775?pdf=render

Internet

http://europepmc.org/articles/PMC3474775?pdf=render

Similar Items